Oncology Brothers: Practice-Changing Cancer Discussions GU Cancer ESMO 2025 Highlights: PSMAddition, Capitello-281, Potomac, Keynote-905, IMVigor011
Oct 23, 2025
Dr. Stephanie Berg, a GU medical oncologist from Dana-Farber Cancer Institute, shares insights on groundbreaking cancer studies presented at ESMO 2025. She discusses the promising impact of lutetium PSMA in prostate cancer and highlights the effectiveness of capivasertib for patients with PTEN loss. The conversation also touches on the combination of durvalumab and BCG for high-risk bladder cancer, alongside innovative ctDNA-guided therapies improving survival rates. Tune in for a deep dive into the complexities of cancer treatment and patient-centered care!
AI Snips
Chapters
Transcript
Episode notes
Earlier PSMA Improves Radiographic Control
- Lutetium-PSMA added to ADT + ARPI improved radiographic PFS in metastatic hormone-sensitive prostate cancer.
- The trial showed higher response rates and immature OS with crossover allowed, suggesting early benefit but pending mature survival data.
AKT Inhibition Helps PTEN-Loss Patients
- Capivasertib added to abiraterone + ADT improved rPFS by about seven and a half months in PTEN-loss prostate cancer.
- The population was <10% after screening thousands, identified by IHC, making it a niche precision-medicine benefit.
Prioritize Sequencing And Shared Decisions
- Discuss sequencing and shared decision-making with patients when multiple effective first-line options exist.
- Consider toxicity, subsequent-line options, and patient goals before choosing PSMA, chemo, PARP, or AKT strategies.